Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

New England Journal of Medicine

Volumn 376, Issue 1, 2017, Pages 32-40

  Hiatt, William R ^a   Fowkes, F Gerry R ^b   Heizer, Gretchen ^c   Berger, Jeffrey S ^d   Baumgartner, Iris ^e   Held, Peter ^f   Katona, Brian G ^h   Mahaffey, Kenneth W ⁱ   Norgren, Lars ^g   Jones, W Schuyler ^c   Blomster, Juuso ^f   Millegård, Marcus ^f   Reist, Craig ^c   Patel, Manesh R ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BERN UNIVERSITY HOSPITAL   (Switzerland)

^f ASTRAZENECA R AND D   (Sweden)

^g Örebro University   (Sweden)

^h Astra Zeneca One Med Immune Way   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CLAUDICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; INTERMITTENT CLAUDICATION; ISCHEMIA; KAPLAN MEIER METHOD; LEG; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PERIPHERAL ARTERIAL DISEASE; VASCULARIZATION;

ADENOSINE; AGED; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; KAPLAN-MEIER ESTIMATE; LEG; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 85008318890     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1611688     Document Type: Article

References (14)

1. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.
2. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197-206.
3. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
4. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-13.
5. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
6. Bonaca MP, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 373: 1791-800.
7. Patel MR, Becker RC, Wojdyla DM, et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO Trial. Eur J Prev Cardiol 2015; 22: 734-42.
8. Bonaca M P, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016; 67: 2719-28.
9. Berger JS, Katona BG, Jones WS, et al. Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. Am Heart J 2016; 175: 86-93.
10. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301: 1909-19.
11. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841-8.
12. Belch J, MacCuish A, Campbell I, et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
13. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.
14. Nambi V, Kimball KT, Bray PF, et al. Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets 2009; 20: 199-205.